Literature DB >> 22205030

Lymph node hypertrophy following Leishmania major infection is dependent on TLR9.

Lucas P Carvalho1, Patricia M Petritus, Alyssa L Trochtenberg, Colby Zaph, David A Hill, David Artis, Phillip Scott.   

Abstract

Control of the protozoan parasite Leishmania major is dependent on establishing a robust T cell response. An early event in the development of an effective T cell response is the expansion (or hypertrophy) of the lymph node draining the site of infection, although the mechanisms involved in this response are not completely understood. In this study, we show that lymph node hypertrophy following L. major infection in mice is associated with increased recruitment of lymphocytes to the lymph node from the blood, and that CD62L-deficient mice, which are unable to recruit cells to the lymph node, develop a chronic infection with L. major. Injection of L. major-activated dendritic cells promoted lymph node hypertrophy, and this correlated with an increase in the expression of CCR7 on dendritic cells, although the upregulation of CCR7 occurred on the bystander (uninfected) dendritic cells rather than those containing parasites. We found that increased CCR7 expression was TLR9-dependent, that TLR9(-/-) dendritic cells migrated less efficiently to the draining lymph node, and that TLR9(-/-) mice exhibited a deficit in lymph node expansion following L. major infection, as well as increased susceptibility. Taken together, to our knowledge, these results are the first to demonstrate that activation of dendritic cells via TLR9 is essential for the induction of lymph node hypertrophy in leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205030      PMCID: PMC3262876          DOI: 10.4049/jimmunol.1101018

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection.

Authors:  L Soong; J C Xu; I S Grewal; P Kima; J Sun; B J Longley; N H Ruddle; D McMahon-Pratt; R A Flavell
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

2.  CD40 ligand is required for protective cell-mediated immunity to Leishmania major.

Authors:  K A Campbell; P J Ovendale; M K Kennedy; W C Fanslow; S G Reed; C R Maliszewski
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

3.  Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity.

Authors:  M Kamanaka; P Yu; T Yasui; K Yoshida; T Kawabe; T Horii; T Kishimoto; H Kikutani
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

4.  Immunoregulatory pathways in murine leishmaniasis: different regulatory control during Leishmania mexicana mexicana and Leishmania major infections.

Authors:  J Alexander; P M Kaye
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

5.  Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis.

Authors:  E M Carvalho; D Correia Filho; O Bacellar; R P Almeida; H Lessa; H Rocha
Journal:  Am J Trop Med Hyg       Date:  1995-09       Impact factor: 2.345

6.  Lymphadenopathy as the first sign of human cutaneous infection by Leishmania braziliensis.

Authors:  A Barral; J Guerreiro; G Bomfim; D Correia; M Barral-Netto; E M Carvalho
Journal:  Am J Trop Med Hyg       Date:  1995-09       Impact factor: 2.345

7.  Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway.

Authors:  Sathit Pichyangkul; Kosol Yongvanitchit; Utaiwan Kum-arb; Hiroaki Hemmi; Shizuo Akira; Arthur M Krieg; D Gray Heppner; V Ann Stewart; Hitoshi Hasegawa; Sornchai Looareesuwan; G Dennis Shanks; R Scott Miller
Journal:  J Immunol       Date:  2004-04-15       Impact factor: 5.422

8.  Lymphadenopathy associated with Leishmania braziliensis cutaneous infection.

Authors:  A Barral; M Barral-Netto; R Almeida; A R de Jesus; G Grimaldi Júnior; E M Netto; I Santos; O Bacellar; E M Carvalho
Journal:  Am J Trop Med Hyg       Date:  1992-11       Impact factor: 2.345

9.  Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major.

Authors:  Pascale Kropf; Marina A Freudenberg; Manuel Modolell; Helen P Price; Shanti Herath; Simone Antoniazi; Chris Galanos; Deborah F Smith; Ingrid Müller
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

10.  Entry of naive CD4 T cells into peripheral lymph nodes requires L-selectin.

Authors:  L M Bradley; S R Watson; S L Swain
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  21 in total

1.  The Wnt Antagonist Dickkopf-1 Promotes Pathological Type 2 Cell-Mediated Inflammation.

Authors:  Wook-Jin Chae; Allison K Ehrlich; Pamela Y Chan; Alexandra M Teixeira; Octavian Henegariu; Liming Hao; Jae Hun Shin; Jong-Hyun Park; Wai Ho Tang; Sang-Taek Kim; Stephen E Maher; Karen Goldsmith-Pestana; Peiying Shan; John Hwa; Patty J Lee; Diane S Krause; Carla V Rothlin; Diane McMahon-Pratt; Alfred L M Bothwell
Journal:  Immunity       Date:  2016-02-09       Impact factor: 31.745

2.  Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major.

Authors:  Alex G Peniche; Yaneth Osorio; Adam R Renslo; Doug E Frantz; Peter C Melby; Bruno L Travi
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

3.  Role of Toll-like receptor 9 signaling in experimental Leishmania braziliensis infection.

Authors:  Tiffany Weinkopff; Anita Mariotto; Gregoire Simon; Yazmin Hauyon-La Torre; Floriane Auderset; Steffen Schuster; Haroun Zangger; Nicolas Fasel; Aldina Barral; Fabienne Tacchini-Cottier
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

Review 4.  The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis.

Authors:  Mary-Anne Hartley; Stefan Drexler; Catherine Ronet; Stephen M Beverley; Nicolas Fasel
Journal:  Trends Parasitol       Date:  2014-06-20

5.  Immunoregulatory profile of monocytes from cutaneous leishmaniasis patients and association with lesion size.

Authors:  É L M Vieira; T S L Keesen; P R Machado; L H Guimarães; E M Carvalho; W O Dutra; K J Gollob
Journal:  Parasite Immunol       Date:  2013-02       Impact factor: 2.280

6.  Toll-like receptor 9 signaling in dendritic cells regulates neutrophil recruitment to inflammatory foci following Leishmania infantum infection.

Authors:  Laís Sacramento; Silvia C Trevelin; Manuela S Nascimento; Djalma S Lima-Jùnior; Diego L Costa; Roque P Almeida; Fernando Q Cunha; João S Silva; Vanessa Carregaro
Journal:  Infect Immun       Date:  2015-09-14       Impact factor: 3.441

7.  Involvement of L-selectin expression in Burkholderia pseudomallei-infected monocytes invading the brain during murine melioidosis.

Authors:  Yao-Shen Chen; Hsi-Hsun Lin; Pei-Tan Hsueh; Wei-Fen Ni; Pei-Ju Liu; Pei-Shih Chen; Hsin-Hou Chang; Der-Shan Sun; Ya-Lei Chen
Journal:  Virulence       Date:  2016-09-19       Impact factor: 5.882

8.  Do you see what I see: Recognition of protozoan parasites by Toll-like receptors.

Authors:  Debopam Ghosh; Jason S Stumhofer
Journal:  Curr Immunol Rev       Date:  2013-08

9.  Intermediate monocytes contribute to pathologic immune response in Leishmania braziliensis infections.

Authors:  Sara Passos; Lucas P Carvalho; Rúbia S Costa; Taís M Campos; Fernanda O Novais; Andréa Magalhães; Paulo R L Machado; Daniel Beiting; David Mosser; Edgar M Carvalho; Phillip Scott
Journal:  J Infect Dis       Date:  2014-08-19       Impact factor: 5.226

10.  UNC93B1 and nucleic acid-sensing Toll-like receptors mediate host resistance to infection with Leishmania major.

Authors:  Bruno Luiz Fonseca Schamber-Reis; Patricia M Petritus; Braulia C Caetano; Espiridion R Martinez; Kendi Okuda; Douglas Golenbock; Phillip Scott; Ricardo T Gazzinelli
Journal:  J Biol Chem       Date:  2013-01-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.